Downregulation of EZH2 inhibits epithelial–mesenchymal transition in enzalutamide‐resistant prostate cancer
- 20 July 2023
- journal article
- research article
- Published by Wiley in The Prostate
- Vol. 83 (15) , 1458-1469
Abstract
Background: Androgen signaling inhibitors (ASI) have been approved for treatment of metastatic castration‐resistant prostate cancer (mCRPC). However, the limited success of ASI in clinic justifies an urgent need to identify new targets and develop novel approaches for treatment. EZH2 significantly increases in prostate cancer (PCa). Little is understood, however, regarding the roles of EZH2 in Enzalutamide‐resistant (EnzR) mCRPC.Methods: We firstly investigated the levels of EZH2 and the altered pathways in public database which was comprised with primary and metastatic PCa patient tumors. To elucidate the roles of EZH2 in mCRPC, we manipulated EZH2 in EnzR PCa cell lines to examine epithelial‐mesenchymal transition (EMT). To dissect the underlying mechanisms, we measured the transcription levels of EMT‐associated transcription factors (TFs).Results: We found that EZH2 was highly expressed in mCRPC than that of primary PCa tumors and that EnzR PCa cells gained more EMT characteristics than those of enzalutamide‐sensitive counterparts. Further, loss of EZH2‐induced inhibition of EMT is independent of polycomb repressive complex 2 (PRC2). Mechanistically, downregulation of EZH2 inhibits transcription of EMT‐associated TFs by repressing formation of H3K4me3 to the promotor regions of the TFs.Conclusion: We identified the novel roles of EZH2 in EnzR mCRPC. EnzR PCa gains more EMT properties than that of enzalutamide‐sensitive PCa. Loss of EZH2‐assocaited inhibition of EMT is PRC2 independent. Downregulation of EZH2 suppresses EMT by impairing formation of H3K4me3 at the promotor regions, thus repressing expression of EMT‐associated TFs.Keywords
Funding Information
- National Cancer Institute (CA157429, CA196634, CA256893, CA264652)
This publication has 36 references indexed in Scilit:
- Anti-androgen receptor ASC-J9 versus anti-androgens MDV3100 (Enzalutamide) or Casodex (Bicalutamide) leads to opposite effects on prostate cancer metastasis via differential modulation of macrophage infiltration and STAT3-CCL2 signalingCell Death & Disease, 2013
- EZH2 Oncogenic Activity in Castration-Resistant Prostate Cancer Cells Is Polycomb-IndependentScience, 2012
- EZH2 Generates a Methyl Degron that Is Recognized by the DCAF1/DDB1/CUL4 E3 Ubiquitin Ligase ComplexMolecular Cell, 2012
- The mutational landscape of lethal castration-resistant prostate cancerNature, 2012
- A complex Polycomb issue: the two faces of EZH2 in cancerGenes & Development, 2012
- TNF/p38α/Polycomb Signaling to Pax7 Locus in Satellite Cells Links Inflammation to the Epigenetic Control of Muscle RegenerationCell Stem Cell, 2010
- Integrative Genomic Profiling of Human Prostate CancerCancer Cell, 2010
- An oncogene–tumor suppressor cascade drives metastatic prostate cancer by coordinately activating Ras and nuclear factor-κBNature Medicine, 2010
- The Polycomb group proteins bind throughout the INK4A-ARF locus and are disassociated in senescent cellsGenes & Development, 2007
- EZH2 promotes proliferation and invasiveness of prostate cancer cellsThe Prostate, 2007